BR112021015318A2 - Formas cristalinas de um inibidor de jak2 - Google Patents
Formas cristalinas de um inibidor de jak2 Download PDFInfo
- Publication number
- BR112021015318A2 BR112021015318A2 BR112021015318-7A BR112021015318A BR112021015318A2 BR 112021015318 A2 BR112021015318 A2 BR 112021015318A2 BR 112021015318 A BR112021015318 A BR 112021015318A BR 112021015318 A2 BR112021015318 A2 BR 112021015318A2
- Authority
- BR
- Brazil
- Prior art keywords
- crystalline
- degrees
- crystalline form
- compound
- diffraction pattern
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FRFR1902018 | 2019-02-12 | ||
| FR1902018A FR3092581A1 (fr) | 2019-02-12 | 2019-02-12 | Formes cristallines d'un inhibiteur de jak2 |
| PCT/US2020/017764 WO2020167844A1 (en) | 2019-02-12 | 2020-02-11 | Crystalline forms of a jak2 inhibitor |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112021015318A2 true BR112021015318A2 (pt) | 2021-10-05 |
Family
ID=68281482
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112021015318-7A BR112021015318A2 (pt) | 2019-02-12 | 2020-02-11 | Formas cristalinas de um inibidor de jak2 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20220332706A1 (https=) |
| EP (1) | EP3927704A4 (https=) |
| JP (2) | JP2022520083A (https=) |
| KR (1) | KR20210148110A (https=) |
| CN (1) | CN114026088A (https=) |
| AU (1) | AU2020221796A1 (https=) |
| BR (1) | BR112021015318A2 (https=) |
| EA (1) | EA202192237A1 (https=) |
| FR (1) | FR3092581A1 (https=) |
| IL (1) | IL285427A (https=) |
| MX (1) | MX2021009423A (https=) |
| SG (1) | SG11202108607QA (https=) |
| WO (1) | WO2020167844A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112021005518A2 (pt) | 2018-09-25 | 2021-06-29 | Impact Biomedicines, Inc. | métodos para tratar distúrbios mieloproliferativos |
| US12559463B2 (en) * | 2019-02-12 | 2026-02-24 | Impact Biomedicines Inc. | Crystalline forms of a JAK2 inhibitor |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5191391B2 (ja) * | 2005-11-01 | 2013-05-08 | ターゲジェン インコーポレーティッド | キナーゼのビ−アリールメタ−ピリミジン阻害剤 |
| AU2010363329A1 (en) * | 2010-11-07 | 2013-05-09 | Targegen, Inc. | Compositions and methods for treating myelofibrosis |
| TW201316989A (zh) * | 2011-07-21 | 2013-05-01 | Sanofi Sa | 用於治療真性多血症及原發性血小板過多症之組合物及方法 |
| US10040804B2 (en) * | 2016-12-21 | 2018-08-07 | Biotheryx, Inc. | Compounds targeting proteins, compositions, methods, and uses thereof |
-
2019
- 2019-02-12 FR FR1902018A patent/FR3092581A1/fr active Pending
-
2020
- 2020-02-11 JP JP2021547092A patent/JP2022520083A/ja active Pending
- 2020-02-11 CN CN202080027762.4A patent/CN114026088A/zh active Pending
- 2020-02-11 MX MX2021009423A patent/MX2021009423A/es unknown
- 2020-02-11 KR KR1020217029156A patent/KR20210148110A/ko not_active Ceased
- 2020-02-11 SG SG11202108607QA patent/SG11202108607QA/en unknown
- 2020-02-11 WO PCT/US2020/017764 patent/WO2020167844A1/en not_active Ceased
- 2020-02-11 AU AU2020221796A patent/AU2020221796A1/en not_active Abandoned
- 2020-02-11 EA EA202192237A patent/EA202192237A1/ru unknown
- 2020-02-11 BR BR112021015318-7A patent/BR112021015318A2/pt unknown
- 2020-02-11 EP EP20756422.0A patent/EP3927704A4/en active Pending
- 2020-02-11 US US17/430,148 patent/US20220332706A1/en not_active Abandoned
-
2021
- 2021-08-06 IL IL285427A patent/IL285427A/en unknown
-
2024
- 2024-12-05 JP JP2024212168A patent/JP2025032217A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CN114026088A (zh) | 2022-02-08 |
| SG11202108607QA (en) | 2021-09-29 |
| JP2022520083A (ja) | 2022-03-28 |
| WO2020167844A1 (en) | 2020-08-20 |
| JP2025032217A (ja) | 2025-03-11 |
| FR3092581A1 (fr) | 2020-08-14 |
| MX2021009423A (es) | 2021-11-17 |
| AU2020221796A1 (en) | 2021-08-12 |
| IL285427A (en) | 2021-09-30 |
| KR20210148110A (ko) | 2021-12-07 |
| EP3927704A4 (en) | 2022-12-28 |
| US20220332706A1 (en) | 2022-10-20 |
| EP3927704A1 (en) | 2021-12-29 |
| EA202192237A1 (ru) | 2021-12-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2623608T5 (es) | Forma cristalina de 4-metil-N-[3-(4-metil-imidazol-1-il)-5-trifluoro-metil-fenil]-3-(4-piridin-3-il-pirimidin-2-il-amino)-benzamida | |
| US10023577B2 (en) | Crystalline form of JAK kinase inhibitor bisulfate and a preparation method thereof | |
| TWI288750B (en) | Isethionate salt of a selective CDK4 inhibitor | |
| JP6720280B2 (ja) | 新規アベキシノスタット塩、関連結晶形態、それらの調製方法およびそれらを含有する医薬組成物 | |
| KR20170032330A (ko) | Ｃ-Ｍｅｔ 억제제의 결정질 유리 염기 또는 이의 결정질 산 염, 및 이들의 제조방법 및 용도 | |
| RU2704795C2 (ru) | Кристаллическая форма бисульфата ингибитора jak и способ ее получения | |
| JP2025032217A (ja) | Ｊａｋ２阻害剤の結晶形態 | |
| CN113840604B (zh) | Jak2抑制剂的结晶形式 | |
| TWI870440B (zh) | 活化素受體樣激酶抑制劑之鹽及晶體形式 | |
| CN110291079A (zh) | 与吡啶酰基哌啶5-ht1f激动剂相关的组合物和方法 | |
| WO2018117267A1 (ja) | 置換ピペリジン化合物の塩 | |
| CN105408329A (zh) | 呈晶体形式的达沙替尼的盐 | |
| CN111278808B (zh) | 2-(5-(4-(2-吗啉代乙氧基)苯基)吡啶-2-基)-n-苄基乙酰胺的固体形式 | |
| US20200216427A1 (en) | Solid state forms of entrectinib | |
| CA3239187A1 (en) | Mono-p-toluenesulfonate of axl kinase inhibitor and crystal form thereof | |
| CN115572298A (zh) | 一种核苷类似物及其盐的晶型、制备方法和应用 | |
| TW201840557A (zh) | (s)-[2-氯-4-氟-5-(7-嗎啉-4-基喹唑啉-4-基)苯基]-(6-甲氧基-嗒𠯤-3-基)-甲醇之結晶型 | |
| WO2020083188A1 (zh) | 一种酪氨酸激酶抑制剂的一马来酸盐的晶型及其制备方法 | |
| TW202039511A (zh) | Mcl-1抑制劑之新結晶型, 其製備方法及包含其之醫藥組合物 | |
| JP2025503010A (ja) | キナーゼ阻害剤の塩結晶形及び遊離塩基結晶形 | |
| JP2021527120A (ja) | 塩形態 | |
| JP7169695B2 (ja) | ピラジノ［２，１－ｃ］［１，２，４］トリアジン化合物の結晶（１） | |
| JP2021527119A (ja) | 塩形態 | |
| TW202506661A (zh) | 一種酪氨酸激酶抑制劑的可藥用鹽、結晶形式及其製備方法 | |
| HK40069001B (zh) | 活化素受体样激酶抑制剂的盐和晶体形式 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B06W | Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette] | ||
| B15K | Others concerning applications: alteration of classification |
Free format text: A CLASSIFICACAO ANTERIOR ERA: C07D 471/04 Ipc: C07D 471/04 (2006.01), A61K 31/506 (2006.01), A61P |